These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 26384929)

  • 1. Recessive mutations in SLC13A5 result in a loss of citrate transport and cause neonatal epilepsy, developmental delay and teeth hypoplasia.
    Hardies K; de Kovel CG; Weckhuysen S; Asselbergh B; Geuens T; Deconinck T; Azmi A; May P; Brilstra E; Becker F; Barisic N; Craiu D; Braun KP; Lal D; Thiele H; Schubert J; Weber Y; van 't Slot R; Nürnberg P; Balling R; Timmerman V; Lerche H; Maudsley S; Helbig I; Suls A; Koeleman BP; De Jonghe P;
    Brain; 2015 Nov; 138(Pt 11):3238-50. PubMed ID: 26384929
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neonatal developmental and epileptic encephalopathy due to autosomal recessive variants in SLC13A5 gene.
    Matricardi S; De Liso P; Freri E; Costa P; Castellotti B; Magri S; Gellera C; Granata T; Musante L; Lesca G; Oertel J; Craiu D; Hammer TB; Møller RS; Barisic N; Abou Jamra R; Polster T; Vigevano F; Marini C
    Epilepsia; 2020 Nov; 61(11):2474-2485. PubMed ID: 33063863
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutations in the Na(+)/citrate cotransporter NaCT (SLC13A5) in pediatric patients with epilepsy and developmental delay.
    Klotz J; Porter BE; Colas C; Schlessinger A; Pajor AM
    Mol Med; 2016 May; 22():310-21. PubMed ID: 27261973
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma Membrane Na⁺-Coupled Citrate Transporter (SLC13A5) and Neonatal Epileptic Encephalopathy.
    Bhutia YD; Kopel JJ; Lawrence JJ; Neugebauer V; Ganapathy V
    Molecules; 2017 Feb; 22(3):. PubMed ID: 28264506
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutations in SLC13A5 cause autosomal-recessive epileptic encephalopathy with seizure onset in the first days of life.
    Thevenon J; Milh M; Feillet F; St-Onge J; Duffourd Y; Jugé C; Roubertie A; Héron D; Mignot C; Raffo E; Isidor B; Wahlen S; Sanlaville D; Villeneuve N; Darmency-Stamboul V; Toutain A; Lefebvre M; Chouchane M; Huet F; Lafon A; de Saint Martin A; Lesca G; El Chehadeh S; Thauvin-Robinet C; Masurel-Paulet A; Odent S; Villard L; Philippe C; Faivre L; Rivière JB
    Am J Hum Genet; 2014 Jul; 95(1):113-20. PubMed ID: 24995870
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel Homozygous Variants of SLC13A5 Expand the Functional Heterogeneity of a Homogeneous Syndrome of Early Infantile Epileptic Encephalopathy.
    Alsemari A; Guzmán-Vega FJ; Meyer BF; Arold ST
    Pediatr Neurol; 2024 Feb; 151():68-72. PubMed ID: 38113697
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SLC13A5 is the second gene associated with Kohlschütter-Tönz syndrome.
    Schossig A; Bloch-Zupan A; Lussi A; Wolf NI; Raskin S; Cohen M; Giuliano F; Jurgens J; Krabichler B; Koolen DA; de Macena Sobreira NL; Maurer E; Muller-Bolla M; Penzien J; Zschocke J; Kapferer-Seebacher I
    J Med Genet; 2017 Jan; 54(1):54-62. PubMed ID: 27600704
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disruption of the sodium-dependent citrate transporter SLC13A5 in mice causes alterations in brain citrate levels and neuronal network excitability in the hippocampus.
    Henke C; Töllner K; van Dijk RM; Miljanovic N; Cordes T; Twele F; Bröer S; Ziesak V; Rohde M; Hauck SM; Vogel C; Welzel L; Schumann T; Willmes DM; Kurzbach A; El-Agroudy NN; Bornstein SR; Schneider SA; Jordan J; Potschka H; Metallo CM; Köhling R; Birkenfeld AL; Löscher W
    Neurobiol Dis; 2020 Sep; 143():105018. PubMed ID: 32682952
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Consequences of NaCT/SLC13A5/mINDY deficiency: good versus evil, separated only by the blood-brain barrier.
    Kopel JJ; Bhutia YD; Sivaprakasam S; Ganapathy V
    Biochem J; 2021 Feb; 478(3):463-486. PubMed ID: 33544126
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of naturally occurring mutations in the human uptake transporter NaCT important for bone and brain development and energy metabolism.
    Selch S; Chafai A; Sticht H; Birkenfeld AL; Fromm MF; König J
    Sci Rep; 2018 Jul; 8(1):11330. PubMed ID: 30054523
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metformin, valproic acid, and starvation induce seizures in a patient with partial SLC13A5 deficiency: a case of pharmaco-synergistic heterozygosity.
    Kopel J; Grooms A; Ganapathy V; Clothier J
    Psychiatr Genet; 2021 Feb; 31(1):32-35. PubMed ID: 33290383
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analyses of SLC13A5-epilepsy patients reveal perturbations of TCA cycle.
    Bainbridge MN; Cooney E; Miller M; Kennedy AD; Wulff JE; Donti T; Jhangiani SN; Gibbs RA; Elsea SH; Porter BE; Graham BH
    Mol Genet Metab; 2017 Aug; 121(4):314-319. PubMed ID: 28673551
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery and characterization of novel inhibitors of the sodium-coupled citrate transporter (NaCT or SLC13A5).
    Huard K; Brown J; Jones JC; Cabral S; Futatsugi K; Gorgoglione M; Lanba A; Vera NB; Zhu Y; Yan Q; Zhou Y; Vernochet C; Riccardi K; Wolford A; Pirman D; Niosi M; Aspnes G; Herr M; Genung NE; Magee TV; Uccello DP; Loria P; Di L; Gosset JR; Hepworth D; Rolph T; Pfefferkorn JA; Erion DM
    Sci Rep; 2015 Dec; 5():17391. PubMed ID: 26620127
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel homozygous SLC13A5 whole-gene deletion generated by Alu/Alu-mediated rearrangement in an Iraqi family with epileptic encephalopathy.
    Duan R; Saadi NW; Grochowski CM; Bhadila G; Faridoun A; Mitani T; Du H; Fatih JM; Jhangiani SN; Akdemir ZC; Gibbs RA; Pehlivan D; Posey JE; Marafi D; Lupski JR
    Am J Med Genet A; 2021 Jul; 185(7):1972-1980. PubMed ID: 33797191
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Carbamazepine efficacy in a severe electro-clinical presentation of SLC13A5-epilepsy.
    Santalucia R; Vilain C; Soblet J; De Laet C; Vuckovic A; König J; Aeby A
    Ann Clin Transl Neurol; 2022 Jul; 9(7):1095-1099. PubMed ID: 35633140
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structure and inhibition mechanism of the human citrate transporter NaCT.
    Sauer DB; Song J; Wang B; Hilton JK; Karpowich NK; Mindell JA; Rice WJ; Wang DN
    Nature; 2021 Mar; 591(7848):157-161. PubMed ID: 33597751
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SLC13A5 Deficiency Disorder: From Genetics to Gene Therapy.
    Goodspeed K; Liu JS; Nye KL; Prasad S; Sadhu C; Tavakkoli F; Bilder DA; Minassian BA; Bailey RM
    Genes (Basel); 2022 Sep; 13(9):. PubMed ID: 36140822
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Defective enamel and bone development in sodium-dependent citrate transporter (NaCT) Slc13a5 deficient mice.
    Irizarry AR; Yan G; Zeng Q; Lucchesi J; Hamang MJ; Ma YL; Rong JX
    PLoS One; 2017; 12(4):e0175465. PubMed ID: 28406943
    [TBL] [Abstract][Full Text] [Related]  

  • 19. GRIN1 mutations cause encephalopathy with infantile-onset epilepsy, and hyperkinetic and stereotyped movement disorders.
    Ohba C; Shiina M; Tohyama J; Haginoya K; Lerman-Sagie T; Okamoto N; Blumkin L; Lev D; Mukaida S; Nozaki F; Uematsu M; Onuma A; Kodera H; Nakashima M; Tsurusaki Y; Miyake N; Tanaka F; Kato M; Ogata K; Saitsu H; Matsumoto N
    Epilepsia; 2015 Jun; 56(6):841-8. PubMed ID: 25864721
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A specialized metabolic pathway partitions citrate in hydroxyapatite to impact mineralization of bones and teeth.
    Dirckx N; Zhang Q; Chu EY; Tower RJ; Li Z; Guo S; Yuan S; Khare PA; Zhang C; Verardo A; Alejandro LO; Park A; Faugere MC; Helfand SL; Somerman MJ; Riddle RC; de Cabo R; Le A; Schmidt-Rohr K; Clemens TL
    Proc Natl Acad Sci U S A; 2022 Nov; 119(45):e2212178119. PubMed ID: 36322718
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.